From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates dominated Europe’s leading cancer conference over the weekend. Two years after a…
Exelixis’ oral tyrosine kinase inhibitor (TKI) was tied to a 20% reduced risk of death from colorectal cancer, appearing to validate the biopharma’s hopes of having another “franchise molecule” on…
Moderna’s efforts to advance its cancer pipeline “make sense” against the backdrop of a more skeptical U.S. government attitude toward infectious disease vaccines, the company’s oncology chief told Fierce. The…
Europe’s leading cancer conference may be swimming in antibody-drug conjugate (ADC) data, but AstraZeneca remains convinced that its in-house pipeline sets the pharma apart. The U.K.-based drugmaker has earned its…
Tubulis’ next-generation antibody-drug conjugate (ADC) has been tied to an overall response rate (ORR) of 59% as the German biotech tastes its first clinical success. The Munich-based company is testing…
GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates (ADCs), but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own…
Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored a 32% objective response rate in patients with treatment-resistant mesothelioma. In…
Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash conditions of an acquisition inked back in August. The changes…
For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a…
Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring a 75% objective response rate (ORR) in patients with advanced melanoma after…